Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160733 | 0.87 | ALDH1A1 (0.43) | ALDH1A1TSHR | |
| SCHEMBL1968530 | 0.80 | — | — | |
| SCHEMBL11573651 | 0.78 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL19502080 | 0.78 | — | — | |
| SCHEMBL6181 | 0.76 | GAA (0.52) | ALDH1A1CA12 | |
| SCHEMBL10499586 | 0.74 | LMNA (0.42) | ALDH1A1TSHR | |
| SCHEMBL10724862 | 0.74 | CA12 (0.39) | CA12CA14 | |
| SCHEMBL9479402 | 0.73 | ALDH1A1 (0.35) | ALDH1A1POLB | |
| SCHEMBL29274963 | 0.73 | CA1 (0.33) | CA12 | |
| SCHEMBL10499002 | 0.72 | NAAA (0.39) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4973750-A | Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols | SCHERING CORPORATION (US) | 1990-11-27 | — | — | US | claimed |
| US-20070208062-A1 | 3-(4-(2-DIHYDROISOXAZOL-3-YLPYRIDIN-5-YL)PHENYL)-5-TRIAZOL-1-YLMETHYLOXAZOLIDIN-2-ONE DERIVATIVES AS MAO INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2007-09-06 | — | — | US | disclosed |
| EP-1753753-A1 | 3-(4-(2-DIHYDROISOXAZOL-3-YLPYRDIN-5-YL)PHENYL)-5-TRIAZOL-1-YLMETHYLOXAZOLIDIN-2-ONE DERIVATIVES AS MAO INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005116024-A1 | 3- (4- (2-DIHYDROISOXAZOL-3-YLPYRIDIN-5-YL) PHENYL) -5-TRIAZOL-1-YLMETHYLOXAZOLIDIN-2-ONE DERIVAIVES AS MAO INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208062-A1 | 3-(4-(2-DIHYDROISOXAZOL-3-YLPYRIDIN-5-YL)PHENYL)-5-TRIAZOL-1-YLMETHYLOXAZOLIDIN-2-ONE DERIVATIVES AS MAO INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MAOA, MAOB, TH | ALDH1A1 176/4885CA12 4728/4885CA14 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.